GSK: A case study

GlaxoSmithKline is facing serious charges of misconduct as enforcement grows fierce. The entwining Chinese anti-bribery laws, the US FCPA and UK Bribery Act call for immediate attention to risks and compliance on both a national and global scale

11 minute readJuly 08, 2014 at 08:03 AM

clpstaff

& clp articles

The Chinese government has substantially beefed up its anti-corruption enforcement in recent years, resulting in arrests and trials of high-level state officials and prominent executives of state-owned entities (SOEs) as

A Subscription is Required to Access this Content

Subscribe to China Law & Practice today for:

✓ A database of 3000+ essential documents, including key PRC laws translated into English
✓ Newsletters with business-critical and sector-specific updates
✓ Premium mobile access with timely analysis on China's fast-changing market

Already a Subscriber? Log In. Sign In Now

Questions? Contact us at [email protected] | 1-855-808-4530 (Americas) | 44(0) 800 098 386009 (UK & Europe)